In a move set to bolster Russia’s industrial base, chemical producer Novokhim will build a significant new manufacturing plant for glyoxal — a versatile compound crucial for pharmaceuticals, agriculture, and oil extraction. The facility, slated to launch in 2027 within the Tomsk Special Economic Zone, where Novochem is a registered resident, is designed to produce 10,000 metric tons annually, directly supporting Russia’s long-term push for import substitution and supply chain resilience.
Glyoxal might not be a household name, but its uses are foundational across global industries. For pharmaceuticals, it serves as a key building block in drug synthesis. In agriculture, it is used in crop protection products. For energy, it functions as a component in fluids for oilfield operations. This new plant, therefore, isn’t just adding chemical output — it’s strengthening Russia’s domestic capacity in several strategic sectors simultaneously.
Novokhim’s portfolio also includes the development of medical-grade biopolymers, advanced flame-retardant additives, and specialized industrial cleaning agents, indicating a clear focus on high-value, innovation-driven segments of the chemical market.
For international observers and businesses, particularly in the pharmaceutical and agrochemical sectors, the emergence of a new, large-scale glyoxal producer offers a signal of potential future supply diversification. As companies worldwide reassess supply chain geography and resilience, a new production node of this scale is a concrete example of how national industrial policy is translating into increased self-sufficiency.

